Read by QxMD icon Read

Journal of Viral Hepatitis

Hyung Joon Yim, In Hee Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Chang Wook Kim, So Young Kwon, Sang Hoon Park, Myung Seok Lee, Soon Ho Um, Kwan Soo Byun
Entecavir 0.5 mg (ETV) is widely used among treatment-naïve chronic hepatitis B (CHB) patients. However, 10%-30% of patients show partial virologic response (PVR) to the drug. If the hepatitis B virus (HBV) continues to replicate, the underlying liver disease may progress. Herein, we compared the efficacy of switching to tenofovir disoproxil fumarate (TDF) with that of continuing ETV in CHB patients with PVR to ETV. This was an open-label randomized controlled trial including CHB patients who had been receiving 0...
May 17, 2018: Journal of Viral Hepatitis
Misuzu Fujita, Masaya Sugiyama, Yasunori Sato, Kengo Nagashima, Sho Takahashi, Masashi Mizokami, Akira Hata
This study aimed to determine the incidence and risk factors for hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) undergoing immunosuppressive therapy. The National Database of Japan, in which insurance claim data have been comprehensively accumulated, was utilized. The subjects were 76,641 RA patients who were plausibly initiated on immunosuppressive therapy from April 2013 to March 2014. Laboratory tests of the hepatitis B surface antigen, anti-hepatitis B virus surface antibody, and anti-hepatitis B virus core antibody were performed in 28...
May 16, 2018: Journal of Viral Hepatitis
Yechan Jeong, Bora Jin, Hye Won Lee, Hye Jung Park, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Sang Hoon Ahn, Seungtaek Kim
Daclatasvir plus asunaprevir (DCV+ASV) treatment is an all-oral direct-acting antiviral (DAA) therapy for the genotype 1b HCV-infected patients. In this study, we investigated how resistance-associated substitutions (RASs) evolved after treatment failures and assessed the effect of those substitutions on viral fitness. Sequencing of NS5A and NS3 revealed typical RASs after treatment failures. Interestingly, the RASs of NS3 reverted to the wild-type amino acid within one year after treatment failures. However, the RASs of NS5A were stable and did not change...
May 16, 2018: Journal of Viral Hepatitis
Arifa Akram, S M Rashedul Islam, Saif Ullah Munshi, Shahina Tabassum
Transmission of Hepatitis B Virus (HBV) usually occurs due to the transfusion of blood or blood products from chronic HBV (CHB) or occult HBV infected (OBI) patients. Besides serological tests e.g. HBsAg and anti-HBc (total), detection of HBV-DNA is necessary for the diagnosis of OBI patients. Different nucleic acid tests (NATs) including real-time-Polymerase Chain Reaction (qPCR) are used for the detect HBV-DNA. The NATs are expensive and require technical expertise which are barriers to introducing them in resource-limited settings...
May 16, 2018: Journal of Viral Hepatitis
Ana Carolina Cardoso, Renata M Perez, Claudio de Figueiredo-Mendes, Nathalie Carvalho Leite, Henrique Sergio Moraes Coelho, Cristiane A Villela-Nogueira
A novel controlled attenuation parameter (CAP) using FibroScan® has been developed for assessment of liver steatosis. The aim was to evaluate the frequency and associated factors for moderate/severe steatosis evaluated by CAP in CHC patients submitted to transient elastography (TE) by FibroScan® . CHC patients underwent TE with CAP evaluation. The classification of steatosis was defined as: CAP < 222 dB/m = S0; CAP ≥ 222 dB/m and <233dB /m = S1; ≥233 dB/m <290dB/m = S2 and >= 290 dB/m = S3...
May 16, 2018: Journal of Viral Hepatitis
Regan Deming, Mary M Ford, Miranda S Moore, Sungwoo Lim, Ponni Perumalswami, Jeffrey Weiss, Brooke Wyatt, Shuchin Shukla, Alain Litwin, Sheila Reynoso, Fabienne Laraque
Hepatitis C (HCV) is a viral infection that if left untreated can severely damage the liver. Project INSPIRE was a three year HCV care coordination program in New York City (NYC) that aimed to address barriers to treatment initiation and cure by providing patients with supportive services and health promotion. We examined whether enrollment in Project INSPIRE was associated with differences in HCV treatment and cure compared with a demographically similar group not enrolled in the program. INSPIRE participants in 2015 were matched with a cohort of HCV-infected persons identified in the NYC surveillance registry, using full optimal matching on propensity scores and stratified by INSPIRE enrollment status...
May 14, 2018: Journal of Viral Hepatitis
Chien-Yu Cheng, Hao-Hsin Wu, Huachun Zou, Yi-Chun Lo
In Taiwan, an outbreak of acute hepatitis A (AHA) infection has been identified since June 2015. Approximately half of the cases occurred in HIV-infected men who have sex with men (MSM). We used the Taiwan Centers for Disease Control (TCDC)-operated National Disease Surveillance Systems (NDSS) to identify the incidence of AHA during 2011-2016. Between June 2015 and December 2016, a total of 1,268 AHA cases were documented, and 601 cases (47.4%) were co-infected with HIV; the majority of whom were MSM (98.4%)...
May 9, 2018: Journal of Viral Hepatitis
Young Youn Cho, Jeong-Hoon Lee, Young Chang, Joon Yeul Nam, Hyeki Cho, Dong Hyeon Lee, Eun Ju Cho, Dong Ho Lee, Su Jong Yu, Jeong Min Lee, Yoon Jun Kim, Jung-Hwan Yoon
Nucleot(s)ide analogues (NAs) reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. However, the risk of HCC is reportedly higher for NA-treated patients than for patients in the inactive CHB phase. This study aimed to compare the long-term outcomes of CHB patients with NA-induced viral suppression and those of patients with inactive CHB. This retrospective study involved 1,118 consecutive CHB patients whose HBV DNA level was continuously <2,000 IU/mL during follow up with/without antiviral agents...
May 9, 2018: Journal of Viral Hepatitis
Tai-Cheng Zhou, Xin Lai, Mu-Hua Feng, Yang Tang, Liang Zhang, Jia Wei
Hepatitis B e antigen (HBeAg) seroconversion is considered to have significantly favorable clinical outcomes for patients with chronic hepatitis B (CHB). However, inconsistent study results suggest that hepatocellular carcinoma (HCC) still occurs in patients with HBeAg seroconversion. We performed a systematic review and meta-analysis to determine the incidence of HCC in patients with CHB after HBeAg seroconversion. Web of Science, PubMed and EMBASE databases were searched through July 2017. The incidence of HCC in CHB patients after HBeAg seroconversion was pooled using a random-effects model or fix-effects model...
May 9, 2018: Journal of Viral Hepatitis
Jian Wang, Juan Xia, Rui Zhang, Xiaomin Yan, Yue Yang, Xiang-An Zhao, Haiyan Chang, Guiyang Wang, Guangmei Chen, Yong Liu, Yuxin Chen, Bei Jia, Zhaoping Zhang, Weimao Ding, Rui Huang, Chao Wu
Identifying the degree of liver inflammation is critical for therapeutic judgment of patients with chronic hepatitis B(CHB). However, we lack indexes which can accurately predict significant liver inflammation in CHB patients. This study aimed to develop a simple predictive index for liver inflammation in CHB using routine clinical parameters. 519 CHB patients who underwent liver biopsy were enrolled and randomly divided into training(n=346) and validation cohorts(n=173). Based on routine clinical parameters, gamma-glutamyl transpeptidase(GGT)(P=0...
May 9, 2018: Journal of Viral Hepatitis
Heng Chi, Angie Japhary, Robert A de Man, Robert J de Knegt, Harry L A Janssen, Bettina E Hansen
We investigated the incidence and predictors of non-adherence towards clinic visits in chronic hepatitis B (CHB) patients on entecavir or tenofovir treatment. This was a retrospective study of CHB patients treated for at least 3 months in a tertiary referral hospital in The Netherlands. Lack of attendance in clinic visits was defined as a missed follow-up visit without notice. 338 patients (48% Caucasian, 37% Asian) were followed for a median of 3.5 years. During 1283 person-years, 183 scheduled follow-up visits were missed in 101 patients resulting in 0...
April 21, 2018: Journal of Viral Hepatitis
Marianne Martinello, Sanjay Bhagani, Edward Gane, Chloe Orkin, Graham Cooke, Gregory J Dore, Kathy Petoumenos, Tanya L Applegate, Elise Tu, Philippa Marks, Nicole Pagani, Jason Grebely, Mark Nelson, Gail V Matthews
Paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 12 weeks is approved for treatment of chronic HCV genotype 1 infection. This study assessed the efficacy of shortened duration paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for eight weeks among people with recent HCV infection. In this open-label single-arm trial conducted in Australia, England and New Zealand, adults with recent HCV (duration of infection <12 months) received paritaprevir/ritonavir/ombitasvir and dasabuvir (with weight-based ribavirin for genotype 1a and 1, no subtype) for eight weeks...
April 16, 2018: Journal of Viral Hepatitis
Oswald Ndi Nfor, Ming-Fang Wu, Tonmoy Debnath, Chun-Te Lee, Wang Lee, Wen-Hsiu Liu, Disline Manli Tantoh, Shu-Yi Hsu, Yung-Po Liaw
Sodium taurocholate co-transporting polypeptide (NTCP) is a functional receptor for hepatitis B virus infection. NTCP rs2296651 is believed to be an Asian-specific variant responsible for HBV susceptibility. We investigated the relationship between rs2296651 and HBV infection in Taiwan based on stratification by gender and menopausal status. We recruited 10017 Taiwan Biobank participants aged 30-70 years with complete genetic data and sociodemographic information. Gender-stratified multivariate logistic regression models were used to determine the relationship between NTCP variant and HBV infection...
April 16, 2018: Journal of Viral Hepatitis
Junyi Shen, Jiaye Liu, Chuan Li, Tianfu Wen, Lvnan Yan, Jiayin Yang
The effects of serum hepatitis B e antigen (HBeAg) on the prognosis of hepatocellular carcinoma (HCC) patients after hepatectomy remain controversial. Our aim was to explore the prognostic significance of serum HBeAg on the prognosis of HCC patients using a propensity matching model. Between January 2009 and March 2015, 953 patients with HCC who underwent hepatectomy in West China Hospital were analyzed. Propensity matching analysis was applied and survival analysis was performed using the Kaplan-Meier method...
April 16, 2018: Journal of Viral Hepatitis
Anders Boyd, Raoul Moh, Sarah Maylin, Mariama Abdou Chekaraou, Nadia Mahjoub, Delphine Gabillard, Xavier Anglaret, Serge Paul Eholié, Constance Delaugerre, Christine Danel, Fabien Zoulim, Karine Lacombe
The nucleotide substitution G1896A on the precore (pc) region has been implicated in virological and serological responses during treatment in hepatitis B virus (HBV)-infected patients. Whether this mutation affects the therapeutic course of HIV-HBV co-infected patients, especially from Western Africa, is unknown. In this prospective cohort study, 86 antiretroviral (ARV)-naïve HIV-HBV co-infected patients from Côte d'Ivoire, initiating ARV-treatment containing lamivudine (n=53) or tenofovir (n=33), had available baseline pc sequences...
April 16, 2018: Journal of Viral Hepatitis
A J Wade, A McCormack, C Roder, K McDonald, M Davies, N Scott, M Wardrop, E Athan, M E Hellard
To increase access to treatment, the Australian government enabled general practitioners (GPs) to prescribe direct-acting antivirals (DAA) to treat hepatitis C virus (HCV) - in consultation with a specialist if inexperienced in HCV management. This study describes the establishment and outcomes of a remote consultation pathway supporting GPs to treat HCV. Key stakeholders from primary and tertiary healthcare services in the Barwon South Western region developed and implemented an HCV remote consultation pathway...
April 16, 2018: Journal of Viral Hepatitis
Anthony Cousien, Viet Chi Tran, Sylvie Deuffic-Burban, Marie Jauffret-Roustide, Guillaume Mabileau, Jean-Stéphane Dhersin, Yazdan Yazdanpanah
Direct-acting antivirals (DAAs) represent an opportunity to improve hepatitis C virus (HCV) care cascade. This, combined with improved harm reduction interventions may lead to HCV elimination especially in people who inject drugs (PWID). We assessed the effectiveness/cost-effectiveness of improvements in harm reduction and chronic hepatitis C (CHC) care cascade in PWID in France. We used a dynamic model of HCV transmission and CHC natural history and evaluated: improved needle/syringe programs-opioid substitution therapies, faster diagnosis/linkage to care, earlier treatment initiation, alone and in combination among active PWID (mean age=36)...
April 16, 2018: Journal of Viral Hepatitis
Ivana Carey, Ruth Byrne, Kathryn Childs, Mary Horner, Matthew Bruce, Bo Wang, Geoffrey Dusheiko, Kosh Agarwal
Tubular renal toxicity is a side-effect of long-term therapy with nucleos(t)ide analogue(s) (NA) in chronic hepatitis B (CHB). There are no established surrogate markers in plasma of early NA-related toxicity. Neutrophil gelatinase-associated lipocalin (NGAL) is a protein produced by tubular cells following renal damage. We aimed therefore, to retrospectively compare conventional renal markers (estimated glomerular filtration rates (eGFR) and urinary protein/creatinine ratio uPCR) with a sensitive biomarker (NGAL) in CHB patients on long-term NA therapy and assess the ability of new markers to predict NA-related renal toxicity (new onset of non-albumin proteinuria)...
April 16, 2018: Journal of Viral Hepatitis
M Gencay, A Seffner, S Pabinger, J Gautier, P Gohl, M Weizenegger, D Neofytos, R Batrla, A Woeste, H S Kim, G Westergaard, C Reinsch, E Brill, P T T Thuy, B H Hoang, M Sonderup, C W Spearman, G Brancaccio, M Fasano, G B Gaeta, T Santantonio, W E Kaminski
An important requirement for a state-of-the-art hepatitis B surface antigen (HBsAg) screening assay is reliable detection of mutated HBsAg. Currently, there is a striking shortage of data regarding the detection rates of in vivo HBsAg mutations for these clinically important assays. Therefore, we compared the detection rates of four commercial HBsAg screening assays using a global cohort of 1553 patients from four continents with known HBV genotypes. These samples, which represent the broadest spectrum of known and novel HBsAg major hydrophilic region (MHR) mutations to date, were analyzed for the presence of HBsAg using the Roche Elecsys® HBsAg II Qualitative, Siemens ADVIA Centaur XP HBsAg II, Abbott Architect HBsAg Qualitative II, and DiaSorin Liaison® HBsAg Qualitative assays, respectively...
April 16, 2018: Journal of Viral Hepatitis
Georgios Angelidakis, Jessica P Hwang, Dima Dandachi, Minas P Economides, Jeff Hosry, Bruno P Granwehr, Harrys A Torres
There have been no large studies on the prevalence of hepatitis C virus antibody (anti-HCV) and the optimal HCV screening strategy in patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients. On the basis of the limited available evidence, the American Society for Blood and Marrow Transplantation and European Conference on Infection in Leukemia recommend universal screening. We aimed to determine the prevalence of anti-HCV and to compare the effectiveness of universal HCV screening versus risk-factor-based and 1945-1965 birth-cohort-based screening at the largest tertiary cancer center in the United States...
April 16, 2018: Journal of Viral Hepatitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"